Macrogenics (MGNX) Other financing activities (2013 - 2025)
Macrogenics (MGNX) posted quarterly Other financing activities of $70.0 million for Q2 2025, up 40.0% quarter-over-quarter from $50.0 million in Q3 2023.
Powered by 
Analysis
Macrogenics (MGNX) Other financing activities (2013 - 2025) Analysis & Trends
Macrogenics (MGNX) has reported Other financing activities for 7 consecutive years, with $70.0 million the latest figure, recorded in Q2 2025.
- In Q2 2025, Other financing activities changed N/A year-over-year to $70.0 million; the TTM figure through Dec 2025 stood at $120.0 million (changed N/A YoY), while the FY2025 annual figure was $70.0 million, changed N/A from the prior year.
- Other financing activities grew to $70.0 million in Q2 2025 per MGNX's latest filing, from $50.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $100.0 million in Q1 2023 and bottomed at $50.0 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Macrogenics | 284.90 Mn | 171.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 70.00 Mn |
| Sep 30, 2023 | 50.00 Mn |
| Mar 31, 2023 | 100.00 Mn |
| Mar 31, 2017 | 108,000.00 |
| Dec 31, 2016 | 538,000.00 |
| Sep 30, 2016 | 1.01 Mn |
| Jun 30, 2016 | 127,000.00 |
| Mar 31, 2016 | 224,000.00 |
| Dec 31, 2015 | 279,000.00 |
| Sep 30, 2015 | 207,000.00 |
| Jun 30, 2015 | 170,000.00 |
| Mar 31, 2015 | 255,000.00 |
| Dec 31, 2014 | 258,000.00 |
| Sep 30, 2014 | 180,000.00 |
| Jun 30, 2014 | 238,000.00 |
| Mar 31, 2014 | 68,000.00 |
| Dec 31, 2013 | 249,000.00 |